Editors’ Choice papers in Thrombosis and Haemostasis

• References

• 1 Weber C, Lip GYH. Highlights and hot topics from 2011 in Thrombosis and Haemostasis. Thromb Haemost 2012; 107: 196-199.
• 2 Weber C, Lip GYH. Editors’ Choice papers in Thrombosis and Haemostasis. Thromb Haemost 2013; 109: 170-173.
• 3 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-86.
• 4 Marín F, Huber K, Lip GY. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual anti-thrombotic therapy. Thromb Haemost 2013; 110: 623-625.
• 5 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
• 6 Lip GY, Andreotti F, Fauchier L. et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
• 7 De Caterina R, Husted S, Wallentin L. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
• 8 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease Thromb Haemost 2013; 110: 1087-1107.
• 9 Wilke T, Groth A, Mueller S. et al. Oral anticoagu-lation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anti-coagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
• 10 Sorensen SV, Kansal AR, Connolly S. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.
• 11 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thrombo-prophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
• 12 Huisman MV, Lip GY, Diener HC. et al. Dabi- gatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
• 13 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
• 14 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
• 15 Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-222.
• 16 Violi F, Perri L, Loffredo L. Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials. Thromb Haemost 2013; 109: 589-595.
• 17 Ferrandis R, Castillo J, de Andrés J. et al. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 2013; 110: 515-522.
• 18 Desai J, Kolb JM, Weitz JI. et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212.
• 19 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabi-gatran, rivaroxaban, apixaban) versus no treat- ment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
• 20 Lindahl TL, Baghaei F, Blixter IF. et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
• 21 Samama MM, Contant G, Spiro TE. et al. Riva-roxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of riva-roxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
• 22 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
• 23 Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral antico-agulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
• 24 Diener HC. Pro: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation”. Thromb Haemost 2013; 110: 493-495.
• 25 Stöllberger C, Finsterer J. Contra: “New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation”. Thromb Haemost 2013; 110: 496-500.
• 26 Strüβmann T, Tillmann S, Wirtz T. et al. Platelets are a previously unrecognised source of MIF. Thromb Haemost 2013; 110: 1004-1013.
• 27 Winkler J, Rand ML, Schmugge M. et al. Omi/ HtrA2 and XIAP are components of platelet apop-tosis signalling. Thromb Haemost 2013; 109: 532-539.
• 28 Zhang Y, Liu X, Liu L. et al. Contact- and agonist-regulated microvesiculation of human platelets. Thromb Haemost 2013; 110: 331-339.
• 29 Berger JS, Becker RC, Kuhn C. et al. Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost 2013; 109: 85-92.
• 30 Navarro-Núñez L, Langan SA, Nash GB. et al. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013; 109: 991-998.
• 31 Stevic I, Chan HH, Chander A. et al. Covalently linking heparin to antithrombin enhances pro-thrombinase inhibition on activated platelets. Thromb Haemost 2013; 109: 1016-1024.
• 32 Tan X, Shi J, Fu Y. et al. Role of erythrocytes and platelets in the hypercoagulable status in poly-cythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost 2013; 109: 1025-1032.
• 33 Peter K. Isoform-specific effects of protein phos-phatase 1 on outside-in signalling of integrin aIIbβ3: a story told by genetic manipulation of platelet surrogate cells. Thromb Haemost 2013; 109: 7.
• 34 Hosokawa K, Ohnishi T, Sameshima H. et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 2013; 109: 102-111.
• 35 Saucedo JF, Angiolillo DJ, DeRaad R. et al. SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
• 36 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-33.
• 37 Hayon Y, Dashevsky O, Shai E. et al. Platelet lysates stimulate angiogenesis, neurogenesis and neu-roprotection after stroke. Thromb Haemost 2013; 110: 323-330.
• 38 de Stoppelaar SF, Van’t Veer C, van den Boogaard FE. et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-592.
• 39 Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
• 40 Brouwer MA, Jaspers Focks J, Verheugt FW. High platelet reactivity--the challenge of prolonged anti-coagulation therapy after ACS. Thromb Haemost 2013; 109: 799-807.
• 41 Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109: 825-833.
• 42 McFadyen JD, Jackson SP. Differentiating haemo-stasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859-867.
• 43 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
• 44 Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 910-919.
• 45 Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost 2013; 109: 391-398.
• 46 Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost 2013; 109: 407-415.
• 47 Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109: 416-420.
• 48 Björkqvist J, Jämsä A, Renné T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
• 49 Waeckel L, Potier L, Richer C. et al. Pathophysiol-ogy of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb Haemost 2013; 110: 476-483.
• 50 Scroyen I, Hemmeryckx B, Lijnen HR. From mice to men - mouse models in obesity research: What can we learn?. Thromb Haemost 2013; 110: 634-640.
• 51 Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost 2013; 110: 641-650.
• 52 Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thromb Haemost 2013; 110: 669-680.
• 53 de Boer OJ, Li X, Teeling P. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.
• 54 Carbone F, Nencioni A, Mach F. et al. Pathophysi-ological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110: 501-514.
• 55 Gao C, Xie R, Li W. et al. Endothelial cell phagocytosis of senescent neutrophils decreases procoagu-lantactivity. ThrombHaemost 2013; 109: 1079-1090.
• 56 Leers MP, Keuren JF, Frissen ME. et al. The pro-and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome. Thromb Haemost 2013; 110: 101-109.
• 57 Shantsila E, Tapp LD, Wrigley BJ. et al. CXCR4 positive and angiogenic monocytes in myocardial infarction. Thromb Haemost 2013; 109: 255-262.
• 58 Shantsila E, Tapp LD, Wrigley BJ. et al. Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. Thromb Haemost 2013; 110: 340-348.
• 59 Prinz N, Clemens A, Canisius K. et al. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome Thromb Haemost 2013; 109: 525-531.
• 60 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
• 61 Nieuwenhuizen L, Roosendaal G, Coeleveld K. et al. Haemarthrosis stimulates the synovial fibrino-lytic system in haemophilic mice. Thromb Haemost 2013; 110: 173-183.
• 62 Hugenholtz GC, Meijers JC, Adelmeijer J. et al. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. Thromb Haemost 2013; 109: 948-955.
• 63 Diaz JA, Alvarado CM, Wrobleski SK. et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost 2013; 109: 1158-1169.
• 64 Peter K. Isoform-specific effects of protein phos-phatase 1 on outside-in signalling of integrin aIIbβ3: a story told by genetic manipulation of platelet surrogate cells. Thromb Haemost 2013; 109: 7.
• 65 Hirsch E. Two signalling hands for uPAR. Thromb Haemost 2013; 109: 179.
• 66 Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. ThrombHaemost 2013; 109: 583-584.
• 67 Golder M, Mewburn J, Lillicrap D. In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process. Thromb Haemost 2013; 109: 53-60.
• 68 Pählman LI, Mörgelin M, Kasetty G. et al. Antimicrobial activity of fibrinogen and fibrinogen-de rived peptides-- a novel link between coagulation and innate immunity. Thromb Haemost 2013; 109: 930-939.
• 69 Soya K, Terasawa F, Okumura N. Fibrinopeptide A release is necessary for effective B: b interactions in polymerisation of variant fibrinogens with impaired A: a interactions. Thromb Haemost 2013; 109: 221-228.
• 70 Lima MA, Viskov C, Herman F. et al. Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities. Thromb Haemost 2013; 109: 471-478.
• 71 van Mens TE, Levi M, Middeldorp S. Evolution of Factor V Leiden. Thromb Haemost 2013; 110: 23-30.
• 72 Luu NT, Glen KE, Egginton S. et al. Integrin-sub-strate interactions underlying shear-induced inhibition of the inflammatory response of endothe-lial cells. Thromb Haemost 2013; 109: 298-308.
• 73 Montuori N, Cosimato V, Rinaldi L. et al. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost 2013; 109: 309-318.
• 74 Asare Y, Shagdarsuren E, Schmid JA. et al. En-dothelial CSN5 impairs NF-kB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 2013; 110: 141-152.
• 75 Ylä-Herttuala S, Bentzon JF, Daemen MJAP. et al. Stabilisation of atherosclerotic plaques. Thromb Haemost 2011; 106: 1-19.
• 76 Vuilleumier N, Montecucco F, Spinella G. et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endar-terectomy. Thromb Haemost 2013; 109: 706-715.
• 77 Carbone F, Nencioni A, Mach F. et al. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb Haemost 2013; 109: 854-868.
• 78 Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood micropar-ticles. Thromb Haemost 2011; 105: 396-408.
• 79 Hernández C, Orbe J, Roncal C. et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110: 598-608.
• 80 Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107: 611-618.
• 81 Kaudewitz D, Lee R, Willeit P. et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-615.